Antonina A. Pak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonina A. Pak has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Al Saidi
A’Sharqiyh University
1 shared publication - Aleksander G. Rumyantsev
National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia
1 shared publication - Aleksey S. Kolbin
Pavlov University; Saint Petersburg State University
1 shared publication - Alexander V. Kostyuk
House of Ministries
1 shared publication - Ayman W. El-Hattab
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
1 shared publication - Bakhyt M. M. Baigaliyeva
Association for Assistance to Patients with Rare Diseases in the Republic of Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 26 April 2026
- Published by Sechenov University in The BRICS Health Journal
- Vol. 2 (4) , 45-63
Rare diseases as a global priority: the CIS Orphan Forum and the path toward collaboration with BRICS
The Second Orphan Forum of the Commonwealth of Independent States, held in Moscow on June 26–27, 2025, served as a platform to translate World Health Assembly Resolution 78.11 on rare diseases into coordinated policy action. The Forum convened delegates from eight Commonwealth of Independent States members and representatives from India, the United Arab Emirates, South Africa, and Oman, advancing interregional cooperation. Participants highlighted shared challenges: lack of national strategies and harmonized definitions of rare diseases, gaps in diagnostics and care infrastructure, limited registries, shortages of trained specialists, and unstable funding. The adopted Resolution set four priority domains for joint work: policy and regulatory development; organization of care and workforce capacity; pharmaceutical provision and health technology assessment; and international collaboration. Country presentations showed progress alongside persistent gaps. Priorities include expanding screening, establishing centers of expertise, improving patient pathways, extending reimbursement, introducing accelerated regulatory procedures, and updating clinical guidelines. Recommendations emphasize integrated care, continuity from pediatric to adult services, stronger health technology assessment for orphan medicines, real-world data collection, and managed entry and risksharing agreements. The Forum also concluded that closer cooperation on rare diseases is needed within BRICS, especially to improve the efficiency of orphan medicine development, manufacturing, and procurement through coordinated approaches, demand aggregation, and joint price negotiations.
- 26 April 2026
- Published by Sechenov University in The BRICS Health Journal
- Vol. 2 (4) , 45-63
Open AccessRare diseases as a global priority: the CIS Orphan Forum and the path toward collaboration with BRICS
The Second Orphan Forum of the Commonwealth of Independent States, held in Moscow on June 26–27, 2025, served as a platform to translate World Health Assembly Resolution 78.11 on rare diseases into coordinated policy action. The Forum convened delegates from eight Commonwealth of Independent States members and representatives from India, the United Arab Emirates, South Africa, and Oman, advancing interregional cooperation. Participants highlighted shared challenges: lack of national strategies and harmonized definitions of rare diseases, gaps in diagnostics and care infrastructure, limited registries, shortages of trained specialists, and unstable funding. The adopted Resolution set four priority domains for joint work: policy and regulatory development; organization of care and workforce capacity; pharmaceutical provision and health technology assessment; and international collaboration. Country presentations showed progress alongside persistent gaps. Priorities include expanding screening, establishing centers of expertise, improving patient pathways, extending reimbursement, introducing accelerated regulatory procedures, and updating clinical guidelines. Recommendations emphasize integrated care, continuity from pediatric to adult services, stronger health technology assessment for orphan medicines, real-world data collection, and managed entry and risksharing agreements. The Forum also concluded that closer cooperation on rare diseases is needed within BRICS, especially to improve the efficiency of orphan medicine development, manufacturing, and procurement through coordinated approaches, demand aggregation, and joint price negotiations.